Maintenance everolimus beyond progression in pancreatic NET to control insulinoma syndrome

Endocrine. 2021 Jan;71(1):258. doi: 10.1007/s12020-020-02604-x. Epub 2021 Jan 13.

Authors

Valeria Tovazzi¹, Vittorio D Ferrari¹, Alfredo Berruti²

Affiliations

¹ Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy.
² Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy. alfredo.berruti@gmail.com.

PMID: 33442791
DOI: 10.1007/s12020-020-02604-x

No abstract available

Publication types

Letter
Comment

MeSH terms

Everolimus / therapeutic use
Humans
Hypoglycemia*
Insulinoma*
Pancreatic Neoplasms* / drug therapy
Sirolimus

Substances

Everolimus
Sirolimus